Subcutaneous Immunoglobulin (SCIG) from Grifols.
Xembify is a 20% SCIG product from Grifols, approved for primary humoral immunodeficiency. It offers the same SCIG benefits — stable IgG levels, home self-administration — as other 20% subcutaneous products.
Xembify is FDA-approved for the following indications:
Xembify is administered subcutaneously, typically weekly, via self-infusion at home. Some patients use every-two-week dosing.
The manufacturer offers a patient support program — Grifols Patient Assistance Program — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.grifolspatientassistanceprogram.com.
Treatment with Xembify is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Administration logistics are coordinated by the office team based on the route of therapy and patient preference.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.xembify.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Xembify is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.